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Abstract
Aortic valve replacement is the most commonly performed valve operation. 
It has been shown to be an effective therapy in all age groups, including the very 
elderly (age > 90 years). The most common etiologies for aortic stenosis are calcific 
degeneration, rheumatic disease, and congenital bicuspid valves. The most com-
mon causes of pure aortic regurgitation include annuloaortic ectasia and associated 
dilation of the aortic root, endocarditis, aortic dissection, and rheumatic disease. 
The indications for surgery depend on the pathophysiology and symptoms. The 
choice of the prosthesis can be difficult and depends on multiple clinical and 
lifestyle considerations. Early and late outcomes are generally quite good, even in 
high-risk patients.
Keywords: aortic valve, aortic stenosis, aortic incompetence, valve replacement, 
TAVI, aortic valve repair
1. Introduction
Valve disease still a significant health problem in the developed countries, In 
United states nearly 2.5% of the population has moderate or severe valve disease, 
with increased the prevalence for people older than 64 years and is 13% in those 
older than 75 years [1].
The commonest valve diseases in the elderly are calcific aortic valve disease and 
aortic dilation causing aortic regurgitation [2].
While rheumatic heart disease is the most prevalent pathology of valve disease 
globally, especially in the adolescent and young adults with a projected prevalence 
of 16–20 million, rheumatic fever is the most frequent trigger of valve disease 
in the young, particularly in Africa, India, the Middle East, South America, and 
parts of Australia and New Zealand, China, and Russia [3]. In western countries, 
the incidence of rheumatic disease declined in the latter half of the twentieth 
century, with the occurrence of transitory local episodes. In Africa, endomyocar-
dial fibrosis is a common, poorly investigated pathology that leads to valve disease 
in all ages [4]. On the other hand, in the developed countries valve diseases of 
elderly predominate, particularly calcific aortic stenosis and functional mitral 
regurgitation, with a prevalence of 13% in those older than 75 years reported in 
North America [5–7].
Other pathological conditions like infective endocarditis and drug-induced valve 
disease (5-HT2B receptor agonists) are on the rise [8–10].
Aortic Valve Disease
2
Structural biological valves deterioration would be the future burden on health 
resources world-wide; this is due to its current popularity as a therapeutic option 
even in young patients, mainly to avoid the complications of anticoagulation [11, 12].
Lack of equitable access to health care takes place in all countries, as a conse-
quence of many complex economic and social forces. Because of the escalating 
technological cost of health care around the world, the situation is the same, even 
those industrially developed countries.
The salient global errand is the prevention of rheumatic heart disease, which 
would necessitate cooperation among social, political, and medical programs that 
lead to creating enhancements in living conditions by better housing, nutrition and 
improved access to health care [13–16]. Penicillin for streptococcal throat infections 
and secondary prophylaxis would continue to be a cornerstone in the global fight 
against rheumatic heart disease [17–19]. It is also reported that there was a natural 
reduction in the virulence of streptococcal serotypes, but it happened after the 
incidence of rheumatic fever had declined.
Most of the serum biomarkers that have been shown related to VHD are 
detecting secondary effects on the ventricular myocardium. Biomarkers asso-
ciated with myocardial stress include the natriuretic peptides and GDF-15. 
Troponin is linked to myocardial necrosis, and the micro RNAs, ST2, and 
galectin-3 are associated with myocardial hypertrophy and fibrosis. Of these, 
the natriuretic peptides are the most widely studied, but they are not specific to 
VHD, and there is considerable overlap in serum levels between different clinical 
groups [20–22].
2. Practical anatomy and physiology of the aortic valve
The aortic valve is the last gate the blood pumped from the heart to the rest of 
the organs. It is at the junction between the aorta and the outflow tract of the left 
ventricle. Its function is to maintain unidirectional blood flow during the diastole 
while allowing the blood forward flow with minimal resistance during systole. The 
aortic valve has typically three semilunar cusps (tricuspid) named by their relation-
ship to the coronary Ostia: the left coronary and right coronary, and the third is 
the noncoronary cusp. Cusps are attached to the aortic annulus at the bottom of 
slight dilations of the aorta associated with each cusp (sinuses of Valsalva end at the 
sinotubular junction). The sinotubular junction is the narrowest part of the aortic 
Figure 1. 
Aortic valve anatomy.
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root (Figure 1). The fibrous skeleton supports the aortic valve and is continuous 
with the anterior leaflet of the mitral valve [23, 24].
3. Managing a patient with suspected valvular heart disease
3.1 General principles
Detection of valvular heart disorder can be difficult. The state of the patient may 
range in gravity from asymptomatic to cardiogenic shock. Endocarditis may mimic 
systemic illness, vascular or neurologic condition, while acute aortic incompetence 
may be presented as a primary respiratory disorder (acute asthmatic episode). 
Making a timely, accurate diagnosis, while averting excessive laboratory studies, 
may try the acumen of a seasoned clinician.
Commonly, observing a murmur in a well individual or a patient with symptom 
referable to the cardiovascular system, arouse the suspicion of valvular abnormal-
ity. It is essential to reassure the patients; murmur is not synonymous with heart 
disease. It does represent turbulent blood flow which may result from several 
possible conditions. These include: (i) increased flow secondary to anaemia, 
pregnancy, or a hyperadrenergic state; accelerated flow through a restricted orifice 
(ii) regurgitant flow through a leaking valve; or (iii) abnormal shunting between 
two chambers. In an unselected population, most systolic murmurs are physiologic, 
caused by conditions of increased blood flow [25, 26]. The echocardiogram is the 
best way to evaluate the patients and reassure them [27, 28].
The practical approach to these patients relies upon an open-minded history and 
thorough physical examination.
3.2 History
As in nearly all of medicine, most cues to a diagnosis are from history.
The clinician assessment should not be compromised, trying to spare minutes at 
this stage drain hours in the wasted investigation later.
The patient may provide a history of rheumatic fever, pervious episode of infec-
tive endocarditis, intravenous drug use, use of anorectic medications, carcinoid 
tumours, indwelling vascular devices, dental, genitourinary or gastrointestinal 
procedures; Marfan’s syndrome, syphilis; congenital bicuspid aortic valve; treated 
or untreated coronary artery disease, radiation therapy.
Finally, a history of past surgery increases the risk of future valve problems by 
way of prosthetic valve endocarditis or structural failure.
Family genetics undoubtedly plays a role in so doing; the clinician may identify a 
family with a previously unrecognised genetic mutation and allowed early diagnosis 
of relatives. The social history may provide valuable information. For example, a 
childhood spent in a no industrialised region of the world dramatically increases 
the risk of rheumatic valve disease. History of unprotected sex or intravenous drug 
abuse raises the TE.
Course for valvular heart disease varies widely, ranging from minutes to decades 
dependent on primary pathology and age and risk factors related to patients as well 
as the geographical location in the world.
3.2.1 Dyspnea
Unfortunately, it is also very nonspecific, occurring in nearly any disturbance 
of cardiopulmonary function. Orthopnoea and paroxysmal nocturnal dyspnea are 
somewhat more specific for left ventricular failure.
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3.2.2 Palpitations
The sensation of a rapid or unusually vigorous heartbeat may signal the 
development of atrial fibrillation.
3.2.3 Angina
Maybe the initial manifestation of valvular heart disease.
3.2.4 Weight gain, oedema, and abdominal discomfort
In hospitalised patients, excess extra cellular fluid is first presented as pitting 
oedema overlying the sacrum predominantly; the elevated systemic venous pressure 
is the cause of all the above.
3.3 Physical exam
3.3.1 General appearance
The toxic appearance of acute infection, wasting of cardiac cachexia, the 
distressed facial expression, wet cough, accessory muscle use, and diaphoresis of 
pulmonary oedema, and the cool skin characteristic of poor perfusion.
3.3.2 Vital signs
3.3.2.1 Tachycardia
Skin and mucosa cyanosis of the lips cold sweat (Osler nodes). (Janeway 
lesions), painless red macule lesions of the palms and soles (Janeway lesions), 
conjunctive petechial, and subungual hematomas (splinter haemorrhages).
Central venous pulsations jugular venous pulsation and mean central venous 
pressure (CVP) are often abnormal in valvular heart disease. In most cases, right 
heart failure is secondary left-sided valve disease-causing left heart failure. Less 
direct clues to the level of right atrial pressure; include the presence of pedal 
oedema, sacral oedema, anasarca, tender hepatomegaly, ecchymosis (hepatic 
synthetic dysfunction), hepatojugular pulsation and ascites.
3.3.3 Pulse volume, contour
3.3.3.1 Auscultatory findings
However, auscultation technical skill like any other and improves with repetition 
[29]. Therefore, students’ physicians-in-training reading this text should lose heart, 
but rather, should apply themselves diligently to acquire these valuable bedside 
skills. Listening to patients before and after echocardiographic findings are known 
is particularly helpful.
3.4 Electrocardiography
In majority of patients with aortic valve disease with have abnormal ECG 
which commonly non-specific such as left ventricle hypertrophy, with or without 
repolarization abnormalities is seen on electrocardiography (ECG). Left atrial 
enlargement, left axis deviation and conduction disorders are also common. Atrial 
fibrillation can be seen at late state and in older patients or those with hypertension.
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3.5 Radiography
Pulmonary vascular congestion. Enlargement, valvular calcification, and type 
position of prosthetic valve may all be ascertained plain radiographs. Comparing 
changes over time particularly helpful; hence obtaining previous studies is very 
valuable (Figure 2).
3.6 Echocardiography
Echocardiography is the most valuable tool in valvular heart disease due 
to its portability, ease of use. Low cost, steadily improving resolution, and its 
ability to assess hemodynamics, additional ultrasound-based modalities can 
provide information about cardiac anatomy, function, and hemodynamics. 
These modalities include two dimensional (2D) or B-mode in which sound waves 
are in a fan-like distribution, yielding a real wedge-shaped tomographic image 
of the heart. There are three subtypes of Doppler ultrasound. Continuous-wave 
Doppler, all velocities along a continuous line through the heart are displayed as 
a spectrum over time. In pulse wave Doppler, the sample volume is placed on a 
2D image, and the spectral splay of velocities represents the blood flow velocities 
in this region only.
Tissue Doppler is yet another form of Doppler echocardiography which mea-
sures the velocity of anatomic structures rather than red blood cells; it currently has 
very limited application in valvular heart disease [30, 31].
Hemodynamic assessment. Firstly, the pressure gradient a valve or between two 
chambers can be estimated by taking advantage of the relationship between pres-
sure (P), and velocity (v) as described in is the conservation of flow and different 
diameter, the flow of fluid through one section match flow through the other end. 
Since flow equals the product of orifice area and flow velocity, this principle can 
be stated as Area 1 × Velocity 1 = Area 2 × Velocity 2. This is used explicitly in the 
determination of aortic valve area (Figure 3) [30].
Another hemodynamic measure important valvular heart disease are the rate of 
pressure equilibration between two chambers (e.g. pressure half-time, deceleration).
Cardiac catheterisation and direct measure of intracardiac pressures, ventricu-
lography, aortography, and assessment of coronary vessels before valve surgery all 
continue to be an essential tool in the evaluation of valvular heart disease.
Figure 2. 
Cardiomegaly and pulmonary congestion.
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Occasionally, balloon valvotomy serves an important therapeutic and diagnostic 
role in mitral, and occasionally, aortic stenosis.
Positron emission tomography (PET) is an emerging imaging technique which 
allows improved resolution more flexibility than SPECT, including the possibility 
of imaging metabolic substrates and neural transmitters. In light of its expense and 
dependency mostly cyclotron-produced isotopes, its role in valvular heart disease 
remains to be determined.
3.7 Aortic stenosis
Aortic stenosis (AS) may be to congenital or acquired, and the congenital form 
could be above (supra), below (subvalvular) or at the valve level. A supravalvular is 
a rare form of long and tubular narrowing is associated with, (William’s Syndrome) 
hypercalcemia, mental retardation, and peripheral pulmonic stenosis. Subvalvular 
stenosis may be caused by the septum extending into the outflow tract, a cylindrical 
constriction of the outflow tract or, in hypertrophic cardiomyopathy the obstruc-
tion caused by the anterior movement of the mitral valve leaflets. In some patients, 
this is present only at diminished ventricular (LV) volumes recreated in the echo-
cardiography laboratory by Valsalva cause aortic regurgitation [32].
3.8 Epidemiology and aetiology
Isolated aortic stenosis (AS) is more frequent in men and is found in 2% of 
people 65 years of age and older. The most frequent causes of AS include age-
related calcific degeneration, bicuspid aortic valve, and rheumatic aortic valve. 
The distribution of these causes diverges across age groups and geographic regions. 
Age-related degeneration is the commonest cause of AS in elderly patients. In 
comparison, bicuspid aortic valve calcification accounts for most surgical cases in 
younger patients (>65) [33].
3.9 Pathophysiology
There is 0 gradient exists across the standard aortic valve during the cardiac 
cycle. The cross-sectional area of a normal aortic valve is >2 cm2. While reductions 
in the valve area to 1.5–2.0 leads to minimal pressure gradient, further narrowing 
produces dramatic increases in the mean pressure gradient [34]. In AS, progressive 
obstruction of outflow tract increases afterload ventricular, and wall stress of the 
left ventricle leads to high left ventricular systolic and diastolic pressures, decreased 
aortic pressure, and prolonged left ventricular ejection time.
Figure 3. 
Echocardiogram assessment of aortic valve.
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Obstruction to flow usually develops slowly allowing the LV to adapt by con-
centric thickening hypertrophy serves to reduce wall tension (the law of Laplace 
describes wall tension is proportional to pressure and radius and adversely propor-
tional to thickness). As long as the process of muscular wall thickening keeps pace 
with narrowing of the aortic orifice, the ‘wall tension’ is maintained. Gradually, this 
results in compensatory concentric left ventricular hypertrophy (LVH) to maintain 
ejection fraction [35].
The stability comes at a price, now the hypertrophied walls are less compliant 
and LV less able to fill rapidly. Satisfactory end-diastolic volume becomes heavily 
reliant upon atrial contraction. Atrial fibrillation often precipitates dramatic acute 
congestive heart failure in patients with severe AS. The concentric hypertrophy 
increases myocardial oxygen requirement coupled with reduced coronary flow due 
to deviated diastole and low diastolic pressures, which aggravates subendocardial 
ischemia in the presence of normal coronary artery ventricular arrhythmias are 
common as well. The compensatory mechanism may become insufficient in patients 
with chronic severe AS, resulting in thinning and dilation of the left ventricle, lead-
ing to a decrease in ejection fraction and congestive heart failure [36].
Exertional syncope may develop resulting from peripheral vasodilation induced 
by exercise with the background of a fixed cardiac output. Blood pressure drop may 
reduce cerebral perfusion, below the minimum required for consciousness [37].
A negative balance between oxygen supply and demand is the norm in AS. LVH 
increased afterload, and the long systole increases myocardial oxygen demand. The 
high filling pressure and longer systolic time decrease myocardial oxygen supply by 
reducing myocardial perfusion time. Myocardial ischemia in patients with AS is due 
to the alteration in myocardial oxygen supply and demand even in the absence of 
coronary artery disease.
3.10 Clinical features
3.10.1 Clinical presentation
3.10.1.1 Symptoms
Patients with, mild or moderate AS are usually asymptomatic unless they have the 
coexisting cardiopulmonary disease or infective endocarditis. Patients often remain 
asymptomatic until the ventricle begins to fail. At this initially, they usually develop 
fatigue followed by cardinal symptoms of angina, syncope, and dyspnea expected 
survival following the onset of these symptoms is 2, 3, and 5 years, respectively [38].
In rare instances, sudden tragic death is the first manifestation of the disease. 
Patients may be sedentary; it unclear whether they are inactive by choice or have 
gradually restricted their activity to avoid symptoms. A treadmill stress test under 
close medical supervision may help in their assessment.
3.10.1.2 Physical findings
The classic finding in the assessment of peripheral pulses is a delayed and slowly 
rising wave contour pulsus parvus et tardus. However, it may be absent patients 
with associated aortic regurgitation or in patients with associated aortic regurgita-
tion or calcified, inelastic arteries.
Precordial palpation may reveal a sustained and laterally displaced cardiac 
impulse. Because the hypertrophied LV is noncompliant, the critical contribution 
to filling provided by atrial contraction severe thrill is often palpable at the base 
of the heart.
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3.10.2 Ejection systolic crescendo murmur at the second aortic area
3.10.2.1 Electrocardiogram
Standard features on the electrocardiogram include ventricular hypertrophy 
(LVH) with a strain and a biphasic p wave in V1 corresponding to atrial (LA) hyper-
trophy. Atrioventricular and intra ventricular conduction abnormalities maybe 
when calcification extends from the valve into the induction system.
3.10.2.2 Radiography
The chest X-ray rounding of the left heart border and apex, post stenotic dila-
tion of the aorta calcification of the aortic valve, and pulmonary congestion may be 
apparent. Note, these findings are neither highly sensitive nor specific.
3.10.2.3 Echocardiography
Echocardiography serves as the principal modality for and quantitating AS. 2D 
imaging provides information on chamber size, degree of hypertrophy, LV systolic 
function, valve mobility, and calcification. Doppler measurement of transvalvular 
blood flow velocity can be used to ermine peak and mean pressure gradients using the.
The symptomatic triad of AS is angina, exertional syncope, and symptoms of 
congestive heart failure, such as shortness of breath. The mechanisms for angina 
and congestive heart failure are explained in the previous section. The mechanism 
for syncope is likely related to the blunting of exercise-induced augmentation in 
stroke volume as a result of outflow obstruction coupled with exercise-induced 
peripheral vasodilation. These changes cause a drop in systemic blood pressure 
leading to cerebral hypoperfusion and syncope.
The classic physical finding is a systolic ejection murmur heard loudest at the 
second right intercostal space, which commonly radiates to the carotid arteries. And 
maybe associated with severe cases of AS palpable thrill may be present. Palpation 
of the pulse may reveal a weak and delayed pulse known as pulsus parvus et tardus.
3.11 Diagnosis and grading
The most common method for the diagnosis and grading of AS is two-dimen-
sional transthoracic echocardiography Doppler velocity measurement (Table 1). 
In most patients, this modality can reliably establish aortic jet velocity, aortic valve 
peak and mean gradients, and aortic valve area [39].
3.12 Natural history
Without valve replacement symptomatic AS has a bleak outcome. Numerous 
studies consistently reported survivals of 3 years for angina and syncope and 
1.5–2 years for dyspnea and heart failure. These findings have determined the 
recommendations for timely surgical intervention in patients with symptom-
atic AS. Thirty percent of truly asymptomatic severe AS patients will become 
symptomatic in 2 years with mortality risks of less than 1–5% each year to 5% 
each year. Progression rate correlates with AS severity, which seems to progress 
faster with higher mean gradient. Moderate AS progress, with aortic valve area, 
decreases on average by 0.1 cm2 per cent annually the pressure gradient across 
the valve rises on average by 7 mm Hg per year, and the jet velocity increases by 
0.3 m/s per year [40, 41].
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The definitions of the conditions “low-gradient AS” and “high-gradient AS” 
are the most relevant new changes in the recommendations for the management 
of aortic valve stenosis (AS). Precise thresholds of biomarkers and pulmonary 
hypertension are considered, and the emphasis is focused on computed tomogra-
phy, particularly for assessing the degree of calcification of the aortic valve and for 
planning therapy [42].
3.13 Aortic regurgitation
3.13.1 Epidemiology and aetiology
The reasons of aortic regurgitation (AR) are many and can be credited to a dis-
ruption of any components of the functional unit of the aortic root valve composite 
(e.g., cusps, sinuses of Valsalva, sinotubular junction, annulus). In general, the 
causes can be divided into those that involve the valve cusps (e.g., calcific degen-
eration, congenitally bicuspid valve, infective endocarditis, rheumatic disease, 
myxomatous degeneration) and those that encompass the aortic root (e.g., aortic 
dissection, aortitis of various etiologies such as syphilis, connective tissue disorders 
such as Marfan syndrome) [43].
3.13.2 Pathophysiology
The pathophysiology of AR is determined by the speed of onset and duration 
of the disease process. In acute AR, typically caused by aortic dissection, infective 
endocarditis, trauma, or valve prosthesis failure, there is an abrupt escalation in 
left ventricular end-diastolic volume because of the regurgitation. Since the left 
ventricle has restricted compliance and does not have enough time to gradually 
adapt to the extra volume, the left ventricular end-diastolic pressure (LVEDP) rises 
rapidly [44, 45].
In chronic AR, there is a gradual and stealthy evolution of left ventricular (LV) 
dilation and eccentric hypertrophy because of an increase in left ventricular end-dia-
stolic volume, LVEDP, and wall stress. Dilation of the LV maintains normal systolic 
function and forward flow but requiring extra work to achieve normality. Sooner 
or later, the hypertrophic response is exhausted, and LVEF deteriorates as afterload 
increases, resulting in heart failure and its related clinical presentation [44].
3.13.3 Clinical features
Patients with acute AR present with unexpected or precipitously cardiovascular 
collapse, which is a life-threatening emergency. They often demonstrate isch-
emic symptoms because of the diminished coronary blood flow and heightened 
myocardial oxygen demand. In comparison, patients with chronic AR are often 
asymptomatic for an extended time because of the compensator remodelling of their 
LV mentioned earlier. Once the compensatory response is depleted, the patients 
Parameter Mild Moderate Severe
Aortic valve area (cm2) 1.6–2.5 1.1–1.5 ≤1.0
Mean pressure gradient (mm Hg) <20 20–39 ≥40
Aortic jet velocity (m/s) 2.0–2.9 3.0–3.9 ≥4.0
Table 1. 
The severity of aortic stenosis according to echocardiographic criteria.
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experience heart failure symptoms such as exertional dyspnea, orthopnea, and par-
oxysmal nocturnal dyspnea. Patients may also suffer palpitations and angina [46].
The classic murmur of AR is an early diastolic, blowing, a decrescendo murmur 
heard best at the level of the diaphragm at the left sternal border while the patient is 
sitting, leaning forward, and in deep exhalation.
Classic signs of widened pulse pressure may also be found, including Corrigan 
or water-hammer pulse, De Musset sign (bobbing of the head with heartbeats), 
Quincke pulse (pulsations of the lip and fingers), Traube sign (pistol shot sounds 
over the femoral artery), and Müller sign (pulsations of the uvula).
3.13.4 Diagnostic criteria
Transthoracic echocardiography with Doppler colour-flow is the most useful 
tool for the diagnosis of AR. The jet width and vena contracta width on Doppler 
colour-flow are used to qualitatively assess the severity of AR, whereas the regur-
gitant volume, regurgitant fraction, and regurgitant orifice area are used for the 
quantitative assessment.
3.13.5 Management of aortic valve disease
3.13.5.1 Medical management
Many adverse outcomes in adults with valvular heart disease are due to sequelae 
of the disease process, including atrial fibrillation, embolic events, left ventricular 
(LV) dysfunction, pulmonary hypertension, and endocarditis. Patients with 
valvular heart disease are best cared for in the context of a multidisciplinary heart 
valve clinic [47].
Medical therapy in adults with valvular heart disease focuses on prevention and 
treatment of complications because there are no specific therapies to prevent pro-
gression of the valve disease itself apart from primary and secondary prophylaxis of 
rheumatic fever. Rheumatic fever is a multiorgan inflammatory disease that occurs 
10 days to 3 weeks after group A streptococcal pharyngitis. The clinical diagnosis is 
based on the conjunction of an antecedent streptococcal throat infection and classic 
manifestations of the disease, including carditis, polyarthritis, chorea, erythema 
marginatum, and subcutaneous nodules [48]. Reducing the frequency of strepto-
coccal pharyngitis with benzylpenicillin monthly intramuscular injection helps to 
reduce the progression of Rheumatic heart disease. The risk of recurrent disease is 
related to the number of previous episodes, time interval since the last episode, the 
risk of exposure to streptococcal infections (contact with children or crowded situa-
tions), and patient age. A longer duration of secondary prevention is recommended 
in patients with evidence of carditis or persistent valvular disease than in those with 
no evidence of valvular damage [49].
Endocarditis prophylaxis guidelines recommend antibiotics therapy before 
dental procedures, or other procedures associated with bacteraemia, in adults with 
prosthetic valves but not in patients with native valve disease unless the patient had 
an episode of endocarditis, dental hygiene and gum health are the primary preven-
tive measure to reduce endocarditis [50].
Prevention of embolic events in patients with valvular heart disease, particularly 
those with prosthetic valves, MS, or AF, is a key component of optimal medical 
therapy.
Therapy for the prevention of embolic events in patients with valvular heart 
disease typically includes antiplatelet agents or long-term warfarin anticoagulation 
[51, 52]. There is data on the use of newer anticoagulants, such as direct thrombin 
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inhibitors and anti-Xa agents, for prevention of embolic events in patients with 
valve disease [53]. At the initiation of therapy, a target INR and acceptable range 
are defined by the referring physician for each patient on the basis of published 
guidelines and clinical factors unique to that patient, In addition, patient education 
about anticoagulation, possible dietary and drug interactions, recognition of com-
plications of therapy, and the need for careful monitoring of the INR is provided 
verbally and through the use of a variety of media (such as pamphlets, recorded 
presentations, and computer-based material).
Periodic evaluation of disease severity by echocardiography and clinical evalua-
tion of the LV response to chronic volume and/or pressure overload allows optimal 
timing of surgical and percutaneous interventions. General health maintenance is 
important, including evaluation and treatment of coronary disease risk factors, reg-
ular exercise, standard immunisations. Both pneumococcal and annual influenza 
vaccinations are recommended for all adults older than 65 years and are especially 
important in patients with valvular disease, in whom the increased hemodynamic 
demands of acute infection may lead to cardiac decompensation. In younger 
patients with valve disease, routine immunisation is only indicated in conditions 
associated with immunocompromise are also present and optimal dental care. 
Management of concurrent cardiovascular disease follows standard approaches 
with modification, as needed, based on the potential confounding effects of valve 
haemodynamics. Evaluation of coronary anatomy usually is needed before valve 
surgery because of the high prevalence of coronary disease and improved surgical 
outcomes with concurrent coronary revascularisation.
Periodic noninvasive monitoring is essential for the optimal timing of interven-
tions in patients with valve dysfunction. Disease progression may be evident as 
changes in valve anatomy or motion; an increase in the severity of valve stenosis or 
regurgitation; LV dilation, hypertrophy, or dysfunction in response to pressure and/
or volume overload; or secondary effects of the valvular lesion, such as pulmonary 
hypertension or AF.
Although the goal in the management of patients with valvular disease is to 
avoid symptoms and the need for medical therapy by optimising the timing of 
surgical intervention, some patients have persistent symptoms after surgery, have 
symptoms only in response to superimposed hemodynamic stress (such as preg-
nancy), or are not candidates for surgical intervention. In these situations, medical 
therapy is based primarily on adjustment of loading conditions and control of heart 
rate and rhythm.
Most adverse outcomes of noncardiac surgery in adults with valve disease are 
due to failure to recognise the presence of valve disease preoperatively. When valve 
disease is suspected from history or physical examination findings, echocardiogra-
phy is appropriate to identify and define the severity of any valve lesions. In patients 
with valvular disease undergoing noncardiac surgery, management focuses on 
an accurate assessment of disease severity and symptom status, with appropriate 
hemodynamic monitoring and optimisation of loading conditions in the periopera-
tive period [54].
3.13.5.2 Patient education
Patient education is the key to compliance with periodic non invasive monitor-
ing, prevention of complications, and the early recognition of symptoms in patients 
with valvular heart disease. Each patient should understand the expected long-term 
prognosis, potential complications, typical symptoms, the rationale for sequential 
monitoring, and the indications for surgical intervention. Appropriate educa-
tion avoids needless concern and prompts early reporting of symptoms, allowing 
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optimal timing of surgical intervention. Increasingly, patients are actively involved 
in decisions about the timing of surgery and choice of intervention.
Patients also should be knowledgeable about the risk of infective endocarditis and 
the importance of maintaining optimal oral hygiene, including regular dental care.
Patients undergoing long-term anticoagulation need both education and a 
reliable and available source for consultation regarding warfarin dose, interactions 
with other medications, and prompt evaluation of any complications.
3.13.5.3 Aortic valve replacement
The decision for intervention for a faulty aortic valve needs to incorporate the 
natural history of the medically managed disease, the risks associated with the 
intervention, and longer-term problems that might build up as a result of prosthetic 
valve implantation.
Currently, the heart team plays a decisive role in decision making. In addi-
tion, it is prudent to cultivate and set up heart valve centres with specialist 
services in order to generate an ideal environment for the treatment of patients 
with valvular heart disease.
3.13.5.4 Management of Aortic valve stenosis
Criteria for decision-making are clear for surgical valve and transcatheter aortic 
valve implantation (TAVI) from the current European guidelines. Recently TAVI is 
also recommended for patients with intermediate surgical risk. Currently, publish 
literature also supports TAVI implantation in low risk patients as non-inferior to 
surgical therapy [55, 56].
For symptomatic, AS recommendations are made with regard to the choice of 
procedure. For high risk (STS score or EuroSCORE II <4% or a log EuroSCORE 
<10%) TAVI is the default choice. Surgical replacement is indicated for patients with 
a low perioperative risk (STS score > 4%). Patients with an intermediate surgical 
risk, the heart team, should consider other criteria for decision making such as 
anatomical and functional parameters [57, 58], and frailty to reach the best option 
for the patients considering the current knowledge.
Current data from two large prospective randomised studies, have confirmed 
that TAVI was noninferior to surgical treatment with regard to mortality, stroke and 
additional endpoints in both in patients with a low perioperative risk (the mean STS 
score in both trials was 1.9%), expansion of the indication for TAVI which would 
also include younger patients, can be expected [59].
3.13.6 Choice of a valve in surgically treated patients
3.13.6.1 Choice of prosthesis
Choice of prosthesis is a complex decision in a patient undergoing AVR with pro-
found long-term consequences for the patient. Currently available prostheses are 
different with regard to key features, such as the requirement of anticoagulation, 
incidence of thromboembolism, durability, ease of implantation, haemodynamic 
performance, and susbtibilty for infection. Currently age-based guidelines do exist, 
but the final choice must be tailored to the individual patient including consider-
ation of general lifestyle and physical activity, surgeon expertise, diseases, espe-
cially those affecting life expectancy, and, ultimately, overall patient preference.
The patient age is a primary factor in prosthesis selection is. Elderly patients 
have lower life expectancy and physical activity than Younger patients. Which place 
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a greater demand on the prosthesis with regard to durability and hemodynamic 
performance. Age has long been recognised as a major determinant of bioprosthesis 
durability. Traditionally target age between 65 and 70 years has been the indications 
for bioprosthesis and like hood of a second operation for structural valve dysfunc-
tion in a life time 65-year-old person is less than 10%. As a result, it is not common 
to choose a mechanical valve in an old patient. Even if the patient is already treated 
with warfarin for another condition, for example AF, which should not necessarily 
favour the choice of a mechanical valve because it converts a relative indication for 
low-level anticoagulation to an absolute indication for higher levels. It also removes 
the option to stop warfarin in a case of a significant bleeding event. Moreover even 
if the patient had previously received mechanical valve, the choice does not man-
date a second mechanical valve, because risk of complications thromboembolic and 
bleeding is higher with two mechanical valves than it is with one.
It is more complex and controversial to choose of prosthesis in patients younger 
than 65 years. Although traditionally, these patients would receive a mechanical 
valve; the current, improved durability in bioprosthesis and lower operative risk 
of a redo operation for a failed prosthesis have increased the number of patients 
younger than 65 years who receive bioprosthesis, including patients in their 50s and 
even younger.
A particular dilemma women of child-bearing age often it is safer avoid warfarin 
so they choose a bioprosthesis, with the knowledge that they will face at least one 
reoperation in their lifetime.
Stentless valves may provide a larger effective orifice area such as the Toronto 
SPV, Freestyle, and Prima Plus valves although the hemodynamic profiles of 
stentless valves are superior to those of stented valves, especially at the smaller sizes 
[42] durability and survival benefits still is unproven [47, 48]. Some reports suggest 
fewer thromboembolic complications [49]. Currently no specifics indication form 
stentless valve. Maybe these hemodynamic benefits justify implanting stentless 
valves in younger active patients.
The use of homografts has declined in recent years as a primary aortic valve 
substitute because without a durability advantage, it is cumbersome to recommend 
their routine while they have limited availability and the cumbersome storage 
requirements. However, their ability to resist infection renders them an excellent 
solution for patients with endocarditis.
The Ross procedure involves replacing the aortic valve with the patient’s own 
pulmonic valve, which have to be is replaced with a homograft or a stentless 
xenograft. The benefits are near-normal haemodynamic and excellent durability; 
the disadvantages are the technical complexity and need for reoperation for the 
homograft or Late AR. The procedure peaked in popularity in the mid to late 1990s, 
but procedure volume has declined since then. On the basis of the data from the 
Ross Procedure International Registry, several centres continue to report excellent 
results [50, 51] although it is now primarily a procedure for paediatric patients, in 
whom the potential for growth is important, and for young adults in their 20s and 
30s when no other good alternatives exist.
3.13.7 Special situations
3.13.7.1 Low-flow, low-gradient aortic valve
The precise assessment within the heart team of the pathology and anatomy, 
as well as the evaluation of the patient, are emphasised in the new graduated 
recommendations regarding low-flow, low-gradient aortic valve stenosis in 
symptomatic patients [60].
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It is also highly recommended to take into account the morphology of the device 
landing zone and the resulting individual risks for TAVI procedures.
For asymptomatic patients with an indication for aortic valve replacement, 
surgical replacement is still the gold standard, because no data are available for this 
patient cohort concerning TAVI treatment.
3.13.7.2 Management of aortic regurgitation
Surgical aortic valve replacement remains the standard gold treatment of aortic 
valve regurgitation (AR). Transcatheter aortic valve implantation (TAVI) plays 
only a minor role. Currently, the JenaValve (JenaValve Technology GmbH, Munich, 
Germany) is the only prosthesis available for pure AR as an investigational device 
[61]. All other prostheses are used off label [61]. Concerning the choice of the 
type of prosthesis, criteria used in aortic stenosis are not merely interchangeable. 
The percentage of oversizing has to be calculated in a different way because of the 
absence annular calcification. Although outcomes have improved with newer-gen-
eration TAVI devices outcomes are still inferior to surgery. In a few circumstances, 
TAVI might be an option for patients with severe AR and high surgical risk.
The class I recommendations for aortic valve intervention, in patients with AR 
according to the 2014 American College of Cardiology and the American Heart 
Association are the following: symptomatic patients with chronic severe AR, 
asymptomatic patients with chronic severe AR and LV dysfunction (ejection frac-
tion < 50%) at rest, and patients with chronic severe AR who are undergoing con-
comitant coronary artery bypass grafting, aortic surgery, or other heart valve surgery.
The class IIa recommendation is for patients with asymptomatic AR and normal 
LV systolic function (ejection fraction > 50%) but with severe LV dilation (end-
systolic diameter > 50 mm). The class IIb recommendation is for patients with 
moderate AR who are undergoing coronary artery bypass grafting, aortic surgery, 
or other heart valve surgery. Aortic valve intervention may also be reasonable in 
asymptomatic patients with chronic severe AR, normal LV systolic function, and 
severe LV dilation (end-diastolic diameter > 65 mm) if the operative risk is low. 
Other considerations can include evidence of progressive LV dilation, declining 
exercise tolerance, or abnormal hemodynamic response to exercise [62, 63].
However, aortic valve repair carries a similar, if not lower, risk of perioperative 
complication with a low risk of valve-related events over time. Similar to mitral valve 
repair for mitral regurgitation, six there is some suggestion that aortic valve interven-
tion should be considered earlier in patients in whom aortic valve repair is likely [64].
Another broad category of patients who undergo aortic valve preservation and 
repair are those with primary aortic pathology involving the aortic root or the 
ascending aorta and varying degrees of associated aortic valvular disease. In these 
patients, the primary indication for intervention is driven by aortic size, discussed 
in the American, European, and Canadian Guidelines.
From a technical perspective, all patients with primary aortic insufficiency are 
potential candidates for repair. However, the success of aortic valve repair is deter-
mined largely by the quality of cusp tissue available. Thus, patients with significant 
leaflet calcification, destruction owing to active endocarditis, or rheumatic involve-
ment are least likely to undergo successful and durable aortic valve repair. In contrast, 
repair has been shown to have good results in patients with bicuspid (and in smaller 
series, unicuspid, and quadricuspid aortic valves), despite the abnormalities in cusp 
anatomy. An important limitation to the universal application of aortic valve repair 
techniques is the lack of surgical expertise and experience in this field; however, this 
is changing rapidly with increasing interest in aortic valve repair. Patients who are 
candidates for repair should be referred to centres with appropriate expertise.
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3.13.7.3 Procedures
Surgery of the aortic valve can now be accomplished with greater safety and 
efficacy in the majority of patients. In patients with higher operative risks, TAVI 
is already a proven acceptable alternative to AVR. The choice of valve prosthesis is 
guided by patient preference, life expectancy, and comorbidities relevant to SVD 
and anticoagulation. Aortic valve repair in the young patient with AR avoids the 
risks associated with valve prostheses, but long-term durability is unknown. Aortic 
root surgery similarly can be performed with the replacement of both the aortic 
valve and aortic wall, but valve-sparing techniques may offer the advantage of dura-
bility equivalent to that of normal native aortic valves with avoidance of prosthetic 
valve-related complications. Reoperative aortic valve and aortic root surgery, like 
isolated AVR, can be performed safely with best outcomes at high-volume centres.
Aortic valve replacement (AVR) is becoming safe despite the elderly population 
of patients is now being treated, with the best outcomes achieved at high-volume 
centres. The standard approach is a median sternotomy aortic valve and aortic root 
replacement. However, minimally invasive approaches, including the upper hemister-
notomy and right anterior thoracotomy (Figure 4), can be performed with equivalent 
safety and better outcomes. The use of stented bioprosthetic valves surpassed the use 
of mechanical valves, homografts, and pulmonary autografts combined, reflecting 
advances in valve technology. The Novel Sutureless valves combine the advantages of 
a surgical AVR procedure (control of aortic atheroemboli, resection of the diseased 
native valve) with transcatheter technique (decreased procedure time, improved 
valve hemodynamic function). Bentall procedure: root replacement with a composite 
valve-graft is the gold standard for aortic root aneurysm (Figure 5). However, for 
patients who want to avoid the long-term oral anticoagulation required for mechani-
cal valves and structural valve deterioration of the bioprosthetic valves, valve-sparing 
aortic root replacement (David or Yacoub procedures) is a good option (Figure 6).
Indications for aortic root replacement include aneurysms of the ascending 
aorta, aortic valve endocarditis with annular abscess, and acute type A aortic 
dissection. The most common indication is an aneurysm of the aortic root or 
ascending aorta. The size threshold for aneurysm repair depends on whether the 
aneurysm is the primary indication for surgery or whether it coexists in a patient 
already requiring cardiac surgery.
Figure 4. 
Aortic valve replacement.
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Figure 5. 
Bio Bentall procedures.
Figure 6. 
Valve sparing repair.
Primary aneurysms of the aortic root are secondary to either genetically medi-
ated disorders or acquired disorders. The acquired disorders include degenera-
tive thoracic aortic aneurysm, chronic aortic dissection, intramural hematoma, 
penetrating atherosclerotic ulcer, mycotic aneurysm, and pseudoaneurysm. 
The size threshold for surgical repair in this group of patients is 5.5 cm for both 
the aortic root and ascending aorta according to class I recommendations by the 
2010 ACC/AHA Guidelines for the Diagnosis and management of Patients with 
Thoracic Aortic Disease developed by a multigroup-sponsored task force [65]. The 
genetically mediated disorders include Marfan syndrome, vascular Ehlers-Danlos 
syndrome, Turner syndrome, BAV, familial thoracic aortic aneurysm and dissec-
tion, and Loeys-Dietz syndrome. These disorders are associated with a greater risk 
of rupture, dissection, and death, in particular Loeys-Dietz syndrome. The size 
threshold for operative intervention in this group of patients is 5.0 cm, according to 
the same guidelines [51]. This recommendation is consistent with a size threshold of 
5.0 cm in patients with BAV in the 2006 ACC/AHA Guidelines for the Management 
of Patients with Valvular Heart Disease [9]. Surgical repair may be considered 
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in patients with Loeys-Dietz syndrome and aortic diameters as small as 4.2 cm, 
depending on imaging modality [66].
Reoperative aortic valve and aortic root surgery can also be performed safely, 
utilisation CT/MRI imaging, meticulous myocardial protection, and safe manage-
ment of existing bypass grafts.
Two devices of aortic valves for percutaneous transcatheter aortic valve implan-
tation (TAVI) have been used in a large number of patients: balloon-expandable and 
self-expanding. Many new valve technologies are in development [67] (Figure 7).
Current data from randomised trials confirmed that TAVI is superior to 
medical therapy in patients with prohibitive risks for surgery, and it is equivalent 
to surgical aortic valve replacement in high-risk and medium-risk patients with 
aortic stenosis [68].
TAVI is technically possible in most patients with aortic stenosis. The larger ques-
tion is when should TAVI be offered? Evaluation should identify patients in whom a 
significant improvement in quality and duration of life is likely and avoid unneces-
sary intervention in patients in whom the procedure can be performed, but the 
benefit is unlikely. For this reason evaluation of neurocognitive functioning, frailty, 
functional status, mobility, and social support is important in patient selection [68].
Transthoracic and transesophageal echocardiography, cardiac computed 
tomography, and invasive angiography are all used to perform anatomic evaluations 
specific to TAVI.
Evaluation of appropriate candidates for TAVI requires a non-competitive team 
approach involving interventional cardiologists with expertise in structural heart 
disease, cardiac and vascular surgeons, anesthesiologists, imaging specialists, and 
specialised nurses. The proper equipment and a minimum volume of TAVI proce-
dures performed per operator are required.
Randomised trials and large registries of TAVI indicate procedural success rates 
of more than 95%, 30-day survival of more than 90%, meaningful improvement in 
the quality of life, and acceptable complication rates (procedure-related stroke < 2%, 
vascular access site complications < 5%, permanent pacemaker rates < 5%) [69].
Experience with TAVI within failed bioprostheses (valve-in-valve procedures) 
has been reported. Critical issues in achieving a successful valve-in-valve procedure 
include an understanding of the manufacturer sizing and labelling of surgical 
bioprostheses and correct positioning of the valve in the valve. Early experience 
suggests that TAVI will be an important option for the treatment of patients with 
failed bioprostheses [70].
More than 100,000 TAVI procedures have been performed to date. Alternatives 
to TAVI include surgical aortic valve replacement, aortic balloon valvuloplasty 
(with or without external beam radiation), and apical-to-aortic conduits.
Figure 7. 
Current commonly implanted TAVI valves.
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3.13.7.4 Outcomes
Data from the STS indicates that the operative mortality for patients 70 years 
of age or older who underwent isolated AVR or AVR with coronary artery bypass 
grafting surgery (CABG) between 1994 and 2003 fell from 10% to less than 6% 
[71]. In the most recent analysis using the STS database on 108,687 patients from 
1997 to 2006 with a mean age of 68 years undergoing isolated AVR, the in-hospital 
mortality was 2.6% with an observed stroke rate of 1.3% and length of stay of 
7.8 days for the year 2006. Among patients 80–85 years of age, 30-day mortality was 
4.9% with an observed stroke rate of 2.0%.
Experience at centres of excellence within the last 5 years has demonstrated 
significantly improved operative mortality, less than 1%, after isolated AVR. The 
incidence of perioperative stroke in these contemporary series ranged from 0% to 
1.9%, and the length of stay was as short as 5 days [72].
In the prospective, randomised, multicenter Placement of Aortic Transcatheter 
Valves (PARTNER) trial comparing high-risk patients (mean STS score 11.8%) 
receiving TAVI or AVR for severe, symptomatic AS, outcomes for both procedures 
were excellent [73]. Patients undergoing AVR (n = 351, mean age 85 years) had a 
30-day mortality of 6.5%, setting a new benchmark for operative outcomes in a 
high-risk cohort of patients treated at centres of excellence [74]. Moreover, com-
parative results showed that early and late strokes and transient ischemic attacks 
were significantly lower in the AVR group than the TAVI group (30 days, 2.4% vs. 
5.5%, respectively, P = 0.04; 1 year, 4.3% vs. 8.3%, respectively, P = 0.04) [75].
Freedom from reoperation depends on both the prosthesis and patient age. 
Although they do not degenerate, modern mechanical valves do have a finite 
reoperation rate of 0.5–1% per year from endocarditis, pannus overgrowth, and 
thrombosis. Actual freedom from reoperation of modern bioprostheses at 15 years 
approaches 100% in elderly patients older than 70 years, but it can be as low as 50% 
in patients younger than 50 years.
3.13.7.5 Complications
The most common complications following aortic valve surgery are similar to 
those of other cardiac surgeries and include stroke (1–4%), deep sternal wound 
infection (1–2%), reoperation for bleeding (1–3%), and myocardial infarction (MI; 
1–5%). Transient heart block is not uncommon, presumably as a result of traction 
or oedema of the bundle of His in the vicinity of the right noncoronary commis-
sure. It usually resolves within 5–6 days of surgery. The risk of complete heart block 
requiring pacemaker insertion is 3–5% [76].
4. Summary
Aortic valve replacement is the most commonly performed valve operation. 
It has been shown to be an effective therapy in all age groups, including the very 
elderly (age > 90 years). The most common etiologies for AS are calcific degen-
eration, rheumatic disease, and congenital bicuspid valves. The most common 
causes of pure aortic regurgitation include annuloaortic ectasia and associated 
dilation of the aortic root, endocarditis, aortic dissection, and rheumatic disease. 
The indications for surgery depend on the pathophysiology and symptoms. The 
choice of the prosthesis can be difficult and depends on multiple clinical and 
lifestyle considerations. Early and late outcomes are generally quite good, even in 
high-risk patients.
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